Point mutations of the BCR-ABL tyrosine kinase domain are considered the predominant cause of imatinib resistance in chronic myeloid leukemia. The expansion of mutant BCR-ABL-positive clones under selective pressure of tyrosine kinase inhibition is referred to as clonal selection; there are few data on the reversibility of this phenomenon.
Introduction
Point mutations of the BCR-ABL tyrosine kinase domain are the major cause of imatinib resistance in chronic myeloid leukemia (CML). [1] [2] [3] Up to now more than 100 mutations have been described affecting more than 70 amino acids causing resistance by heterogeneous molecular mechanisms. [4] [5] [6] Highly sensitive methods for the detection of mutations in the case of suboptimal response have been introduced in the management of CML. 1, 7, 8 Mutant BCR-ABL-positive clones have been shown to pre-exist treatment in imatinib-naïve patients and to outgrow the unmutated clone under the selective pressure of tyrosine kinase inhibition in a process known as clonal selection. [9] [10] [11] [12] Anecdotal cases of reversibility of clonal selection after cessation of treatment with a tyrosine kinase inhibitor (TKI) have been reported. [13] [14] [15] In theory, the proliferative advantage of a resistant clone in the presence of a TKI does not imply a proliferative disadvantage in the absence of the TKI, indicating that the general assumption of clonal deselection after TKI discontinuation remains controversial. Besides, inhibition of drug affinity mutations may also contribute to alterations in the activity and substrate specificity of the BCR-ABL tyrosine kinase suggesting a possible gain or loss of function. 2, [16] [17] [18] [19] Furthermore, clinical studies have revealed mixed dynamics in the outgrowth of mutant clones in the presence of imatinib supporting the notion that the model of clonal selection alone does not fully reflect the in vivo situation. 10, 20, 21 Recently, it has been reported that imatinibresistant mutant clones can disappear in patients receiving treatment with second-generation TKI. 22, 23 In this study we sought to investigate the dynamics of mutant BCR-ABL alleles in 19 CML patients resistant to imatinib and exposed to alternative non-TKI treatment modalities.
Design and Methods

Patients
Between 2001 and 2007, 75 CML patients who had hematologic resistance to TKI therapy due to a BCR-ABL kinase domain mutation detected by direct sequencing were identified (44 males, 31 females; median age 62 years, range 30-80). The disease phase at the start of TKI treatment was chronic phase (n=35), accelerated phase (n=25), and blast crisis (n=15). All patients were initially treated with imatinib; one patient was switched to nilotinib and one to dasatinib after failure of imatinib therapy.
A subgroup of 19 patients (11 males, 8 females; median age 63 years, range 31-73) received subsequent alternative treatment consisting of non-specific chemotherapy (17 after imatinib, one after imatinib/nilotinib, one after imatinib and subsequently after dasatinib, patient n. 8, Table 1 ), and had a follow up of at least 4 months after the change of treatment regimen (median 13 months, range 4-33). The disease phase at the onset of TKI treatment was (Table 1 ). Patient n. 8 was examined for two different mutations at two time-points: the first mutation (E255K) emerged under imatinib treatment and disappeared after its cessation, the second (T315I) occurred under dasatinib treatment. Patient n. 16 showed the D276G mutation under imatinib; this mutation was lost after switching to nilotinib therapy. Subsequently, the T315I mutation emerged which was retrospectively found to have been present in a small clone during the prior imatinib therapy. All patients were included in studies approved by the Heidelberg University Institutional Review Board and gave informed consent to participation in this study according to the Declaration of Helsinki.
Real-time quantitative polymerase chain reaction, direct sequencing
RNA was extracted from total peripheral blood leukocytes and reverse transcribed according to standard methods. 24 Real-time quantitative polymerase chain reaction (PCR) was performed to determine the numbers of transcripts of BCR-ABL and the control genes ABL and b-glucuronidase (GUS). 25, 26 A 675 bp product encoding ABL amino acids 207 to 414 was generated using a heminested PCR to allow specific amplification of the translocated ABL alleles. 3 Products were directly sequenced in both directions and compared with the wild-type ABL sequence (GenBank accession # U07563).
Quantification of the proportion of mutant BCR-ABL alleles
A mutation-specific nested PCR generated transcripts flanking the different mutation sites. The first step used the primers B2B (BCR exon 13) ACAGCATTCCGCTGACCATCAATAAG and A7− (ABL exon 7) AGACGTCGGACTTGATGGAGAACT spanning the BCR-ABL junction site, thus ensuring that the normal unrearranged ABL allele was not amplified and subjected to analysis. The second step comprised mutation-specific primers yielding products of different lengths. Mutation-specific restriction digestion was performed to quantify the proportion of mutant alleles. Mutations led to loss of RsaI (codon 253), MnlI (codon 255), DdeI (codon 315), and NcoI (codon 351) restriction sites. Gel electrophoresis on 1.8% ethidium bromide-stained agarose gels showed the proportion of mutant alleles by differential band intensity of the digested and the undigested transcripts. A correction factor was used to compensate for differences of band intensity due to different transcript lengths ( 
Results
Proportion of mutant BCR-ABL transcripts
The proportion of mutant BCR-ABL transcripts is given by the ratio of mutant BCR-ABL transcripts to total BCR-ABL transcripts (BCR-ABL Overall, the median proportion of mutant transcripts was 97% (range, 38-100%) before cessation of TKI treatment and 8% after cessation of TKI treatment (range, 0-100%; P<0.0001) indicating a relative decline of 88% (range, 13-100%; Table 3 ). The median time to the nadir (lowest proportion) of mutant alleles after cessation of TKI treatment was 6 months (range, 1-26 months; Table 3 ).
Mutations showed different patterns of deselection ( Figure 2A ). The P-loop mutations examined (Y253F/H and E255K) showed an almost complete regression of mutant transcripts under non-specific chemotherapy. In
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Patient
Under Y253H  E255K  T315I  M351T  total  Y253F  Y253H  E255K  T315I  M351T  n=1  n=4  n=5  n=8  n=2   Y253F  Y253H  E255K  T315I  M351T  n=1  n=4  n=5  n=7  n=1   Y253F  Y253H  E255K  T315I  M351T  total   7  7  1  1  1   17  12  8 31 contrast, the median expression of mutant transcripts remained at higher levels for the T315I and M351T mutations. The patterns for T315I were heterogeneous: mutant transcripts declined under the level of threshold in two patients (patients # 14 and 17), whereas three other patients expressed 100% mutant BCR-ABL until the end of follow-up (patients n. 11-13). The median relative decline of the proportion of mutant BCR-ABL transcripts ranged from 52% to 97% for the different subgroups of mutations (Table 4) .
The proportion of mutant transcripts is given by the ratio of mutant BCR-ABL transcripts to total BCR-ABL transcripts (light gray columns). The size of mutant clones is defined by the number of mutant BCR-ABL transcripts divided by the number of transcripts of the control gene GUS, thus reflecting the absolute number of mutant BCR-ABL positive cells (dark gray columns). The number of mutant BCR-ABL positive transcripts was calculated by multiplying the proportion of mutant transcripts by the number of total BCR-ABL transcripts. BCR-ABL/ABL and BCR-ABL/GUS ratios can be converted to BCR-ABL (IS) using conversion factors according to the international scale (IS). (ND, not determined)
Size of mutant clones
While The median size of mutant clones was 12% (range, 2-60%) before and 1.8% (range, 0-55%; P=0.0003) after cessation of TKI treatment, corresponding to a median relative decline of 86% (range, -34-100%, Table 3 ). GUS quantification was not available for two patients (one with a T315I mutation, the other with a M351T mutation).
With regards to the size of the mutant clones instead of the proportion of mutant transcripts, there was less difference in the median decline after treatment cessation among the different subgroups of mutations ( Figure 2B ). The median relative decline of the size of mutant BCR-ABL-positive clones ranged from 70% to 97% for the different subgroups of mutations (Table 4) .
Two patients (patients # 2 and 9) showed a pattern of repeated selection and deselection of the mutant clone after resumption and second cessation of TKI treatment (Figure 3 ).
Discussion
BCR-ABL mutations represent the major cause of resistance after TKI therapy. 3, 4 Here we describe the dynamics of mutant BCR-ABL transcripts for five common mutations in 20 cases of TKI cessation. The majority of patients showed a substantial decline of mutant BCR-ABL expression within months. This demonstrates that after stopping the selective pressure of the TKI the BCR-ABL mutation confers a proliferative disadvantage. The cases of repeated selection and deselection suggest that competing clones show a high susceptibility to the onset of TKI pressure as well as to its withdrawal. However, it has been demonstrated that clonal selection does not always occur. 10, 21 Indeed, in some patients we observed persistence of mutant clones. Additional factors might influence the impact of the proliferative advantage of either clone. In our series three patients harboring the T315I mutation expressed 100% mutant transcripts until the end of follow-up, whereas in two other patients this mutation disappeared completely. The deselection of a T315I mutant clone after cessation of imatinib had previously been shown in a single patient. 14 A gain-of-function of the T315I mutant BCR-ABL tyrosine kinase, which might explain the persistence of the clone, has been discussed, remaining controversial. 17, 18 Compared to the P-loop mutations examined (Y253F/H, E255K) the median decline of the proportion of mutant transcripts was lower with the T315I and M351T mutations (Figure 2A) . This difference disappeared with regard to the size of mutant clones ( Figure 2B ). Some patients showed a decline of the size of the mutant clone due to a declining BCR-ABL/GUS ratio while the proportion of mutant transcripts remained persistently high (patients # 11 and 13). Recently, it has been shown that the MAPK pathway is preferentially activated by imatinib in T315I mutated cells as compared to unmutated cells. 27 These in vitro data suggest that TKI treatment confers the mutant cell clone with increased oncogenic fitness which is lost after cessation of treatment with the TKI. This might explain the decreasing BCR-ABL/GUS ratio after switching to chemotherapy besides the resumption of an effective therapy.
BCR-ABL
Data on non-specific salvage therapy are important for understanding the activity of second-and third-ge neration TKI. 22, 23 The reduction of mutant clones after TKI withdrawal might be due to non-specific effects or the activity of the new TKI administered.
These results are of particular importance for the activity of drugs addressing the T315I mutation. [28] [29] [30] Since we observed the decline of T315I mutant transcripts to a level below the limit of detection of denaturing high performance liquid chromatography (patient n. 17) the ability of the mutant clone to regrow during treatment with another TKI remains open.
We conclude that the deselection of mutant BCR-ABLpositive clones within months after discontinuation of TKI treatment is a common and reproducible phenomenon. The decline of the proportion of mutant transcripts seems to be less frequent in patients harboring the T315I mutation than in patients with mutations of the P-loop region. However, there is hardly a difference in the regression of the calculated absolute amount of mutant transcripts. The high susceptibility of competing clones to changes in selective pressure emphasizes the need for early screening for BCR-ABL mutations in suboptimally responding patients. Discontinuation of TKI treatment might be an option for patients harboring the T315I mutation. The question of whether treatment discontinuation leads to an eradication of the mutant clone or a persistent mutant clone with the probable consequence of repeated clonal selection after resumption of TKI treatment is object of further investigations using highly sensitive methods. 
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